Editors of Blood Select Top 10 Manuscripts from 2016: Studies Include Advancements in Chimeric Antigen Receptor T Cells, Gene Therapy, and Genetic Sequencing

(WASHINGTON, December 21, 2016) — This year, there have been more than 1,000 manuscripts published in Blood, the Journal of the American Society of Hematology. To recognize these achievements, Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD, have selected the top 10 most outstanding manuscripts of 2016. 

“From harnessing the immune system to target untreatable diseases to honing cutting-edge genome editing techniques to correct genetic defects, the promise of cures for many diseases starts with a better understanding of the blood,” said Dr. Löwenberg. “Recognizing hematology as the home of some of science’s most groundbreaking advances, and Blood’s role as the top-cited journal of our field, we are proud to look back at the top papers of 2016.”

To identify the following top manuscripts of the year, the editors considered quality of the work and interest to the field of hematology, judged by how often the paper was accessed or cited. The following articles are listed in no particular order.


Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the flagship journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.

 

CONTACT:   
Stephen Fitzmaurice, American Society of Hematology   
sfitzmaurice@hematology.org; 202-552-4927 

 

Editors of Blood Select Top 10 Manuscripts from 2016: Studies Include Advancements in Chimeric Antigen Receptor T Cells, Gene Therapy, and Genetic Sequencing

Editors of Blood Select Top 10 Manuscripts from 2016: Studies Include Advancements in Chimeric Antigen Receptor T Cells, Gene Therapy, and Genetic Sequencing

News

2 years
9 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Up Next Autoplay
Lymphopenia: How This Affects Clinicians and Treatment Today @CleClinicNews
Lymphopenia: How This Affects Clinicians and Treatment Today @CleClinicNews
Category: Non-Hodgkin Lymphoma
4 Views
Cancer-News 2 days
HORIZON Study #ASH19 @RushMedical
HORIZON Study #ASH19 @RushMedical
Category: Multiple Myeloma
0 Views
ash 2 days
Immune Status, Inflammation Can Predict Mortality @CleClinicNews @CleClinicMD
Immune Status, Inflammation Can Predict Mortality @CleClinicNews @CleClinicMD
Category: Non-Hodgkin Lymphoma
0 Views
Cancer-News 2 days
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Category: Chronic Lymphocytic Leukemia
12 Views
ash 2 days
MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19
MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19
Category: Other
0 Views
ash 2 days
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Category: Multiple Myeloma
2 Views
ash 3 days
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of  Hematology (ASH) 2019 Annual Meeting
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting
Category: Immunotherapy
2 Views
cancernewsupdate 3 days
New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH
New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH
Category: Immunotherapy
3 Views
ash 3 days
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Category: Breast Cancer
2 Views
cancernewsupdate 3 days
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
2 Views
ash 3 days